Literature DB >> 9703200

Muscarinic stimulation of airway smooth muscle cells.

E Roux1, M Molimard, J P Savineau, R Marthan.   

Abstract

1. Acetylcholine, the principal neurotransmitter of the parasympathetic nervous system, is released at both ganglionic synapses and postganglionic neuroeffector junctions and acts by activation of nicotinic and muscarinic cholinoceptors. This review focuses on the effects of postjunctional muscarinic stimulation of airway smooth muscle. 2. On pharmacological criteria, four distinct subtypes of muscarinic cholinoceptor, denoted M1, M2, M3 and M4 receptors, have been identified by use of selective antagonists. Cloned muscarinic cholinoceptors are members of the family of GTP-binding protein-coupled receptors, which are characterized by seven transmembrane (TM) regions connected by intra- and extracellular loops. Between the fifth and the sixth TM regions, muscarinic receptors possess a large intracytoplasmic loop that is considered to be responsible for G-protein-coupling selectivity and exhibits high divergence between the different subtypes. 3. At the site of the smooth muscle itself, both binding and Northern blot studies have demonstrated, in a variety of species, that muscarinic receptor subtypes present are M2 and M3. M2 receptors are coupled to Gi proteins and adenylyl cyclase inhibition and thus to cAMP signaling. M3 receptors are coupled to Gq/11 protein and phosphoinositide hydrolysis and thus to calcium signaling. 4. Muscarinic-induced contraction of airway smooth muscle is mediated by M3 receptors. M2-mediated inhibition of adenylyl cyclase contributes to the prevention of bronchodilation. Cross-talk between muscarinic and beta2 adrenoceptors is likely to be present in airway smooth muscle. The pathophysiological role of this cross-talk requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703200     DOI: 10.1016/s0306-3623(98)00007-x

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  10 in total

Review 1.  Novel pharmacotherapy for burn wounds: what are the advancements.

Authors:  Michael R Hamblin
Journal:  Expert Opin Pharmacother       Date:  2018-12-05       Impact factor: 3.889

2.  Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways.

Authors:  T Ikeda; A S M Anisuzzaman; H Yoshiki; M Sasaki; T Koshiji; J Uwada; A Nishimune; H Itoh; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 3.  Beta2-agonists for asthma: the pediatric perspective.

Authors:  Padmaja Subbarao; Felix Ratjen
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 4.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Authors:  Donald P Tashkin; Leonardo M Fabbri
Journal:  Respir Res       Date:  2010-10-29

5.  Mathematical modelling of ca(2+) oscillations in airway smooth muscle cells.

Authors:  Milan Brumen; Aleš Fajmut; Andrej Dobovišek; Etienne Roux
Journal:  J Biol Phys       Date:  2005-12       Impact factor: 1.365

Review 6.  Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues.

Authors:  Miranda R Andrus; Joyce V Loyed
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane.

Authors:  Hidemi Aritake; Tsutomu Tamada; Koji Murakami; Shunichi Gamo; Masayuki Nara; Itsuro Kazama; Masakazu Ichinose; Hisatoshi Sugiura
Journal:  Pflugers Arch       Date:  2021-05-24       Impact factor: 3.657

Review 8.  Muscarinic receptors and their antagonists in COPD: anti-inflammatory and antiremodeling effects.

Authors:  George Karakiulakis; Michael Roth
Journal:  Mediators Inflamm       Date:  2012-11-24       Impact factor: 4.711

9.  The pivotal role of airway smooth muscle in asthma pathophysiology.

Authors:  Annaïg Ozier; Benoit Allard; Imane Bara; Pierre-Olivier Girodet; Thomas Trian; Roger Marthan; Patrick Berger
Journal:  J Allergy (Cairo)       Date:  2011-12-11

10.  Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD.

Authors:  Anthony D'Urzo
Journal:  Ther Clin Risk Manag       Date:  2013-08-19       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.